Company Overview and News

to your dashboard

Headline News

Tracking George Soros's Portfolio - Q3 2017 Update

2017-11-17 seekingalpha
Soros's 13F portfolio value decreased from $5.62B to $4.20B this quarter. The number of positions increased from 203 to 227. (866-13)

Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

2017-11-08 zacks
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) reported third-quarter of 2017 results wherein both earnings and sales beat expectations on the back of strong performance of eye-care drug Eylea. (45-0)

Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut

2017-11-08 zacks
Jazz Pharmaceuticals Public Limited Company (JAZZ - Free Report) reported third-quarter 2017 adjusted earnings of $3.22 per share, beating the Zacks Consensus Estimate of $2.89. The bottom line also increased 23% from the year-ago figure. (61-0)

Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3

2017-11-08 zacks
The company reported adjusted earnings of $1.97 per share in the reported quarter, down from the year-ago figure of $2.04 due to continued pricing pressure within the Specialty Generics. (66-0)

Buy These 4 Stocks to Profit From Bitcoin's Soaring Popularity

2017-11-08 zacks
Bitcoin is one of the most popular cyrptocurrencies on the market, primarily backed by a rising user base. According to, the market capitalization of the currency presently stands at more than $124.5 billion, much higher than the stock market valuation of  both Goldman Sachs, Inc. (GS - Free Report) and Morgan Stanley (MS - Free Report) , which sit at $94.6 billion and $91.9 billion, respectively. (932-4)

Rockwell Automation (ROK) Lags Q4 Earnings, Issues '18 View

2017-11-08 zacks
Rockwell Automation Inc. (ROK - Free Report) reported adjusted earnings per share of $1.69 in fourth-quarter fiscal 2017 (ended Sep 30, 2017), up 11% from $1.52 recorded in the prior-year quarter. The year-over-year performance was driven by higher sales, partially offset by higher investment spending, incentive compensation. However, earnings missed the Zacks Consensus Estimate of $1.72. Including one-time items, the company’s earnings came in at $1. (62-0)

Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines

2017-11-08 zacks
Shares of Keryx Biopharmaceuticals Inc. (KERX - Free Report) were down almost 17% on Nov 7 despite receiving FDA approval for a label expansion of its lead drug Auryxia. Lower-than-expected sales of Auryxia in the third quarter led to the selloff. (88-0)

Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag

2017-11-08 zacks
Agenus Inc. (AGEN - Free Report) incurred loss of 37 cents per share in line with the Zacks Consensus Estimate. The figure came in narrower the year-ago loss of 47 cents. (109-0)

Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates

2017-11-08 zacks
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) incurred a loss of $1.34 per share in the third quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.23. The figure was also wider than the year-ago loss of $1.21. (41-0)

Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up

2017-11-08 zacks
Nektar Therapeutics’ (NKTR - Free Report) shares increased more than 10% on Nov 7 after reporting better-than-expected third-quarter results with both earnings and sales surpassing estimates. (78-0)

TEGNA (TGNA) Beats Earnings, Revenue Estimates in Q3

2017-11-08 zacks
TEGNA Inc. (TGNA - Free Report) reported impressive financial results in the third quarter of 2017, wherein both the top line and the bottom line outpaced the Zacks Consensus Estimate. (58-0)

Model N (MODN) Reports Narrower-Than-Expected Loss in Q4

2017-11-08 zacks
Model N, Inc. (MODN - Free Report) reported fiscal fourth-quarter 2017 adjusted loss of 6 cents per share, narrower than the year-ago quarter loss of 28 cents per share. The figure  was also narrower than the Zacks Consensus Estimate of a loss of 9 cents per share. (67-0)

Model N's (MODN) CEO Zack Rinat on Q4 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Model N Fourth Quarter Earnings Call. [Operator Instructions]. Please note, this conference is being recorded. I will now turn the conference over to your host, Staci Mortenson of ICR. You may begin. (13-0)

Model N: This Is A Company Going Nowhere

2017-10-02 seekingalpha
Model N's growth has basically flatlined in the past few quarters, underscoring its inability to popularize its software for revenue management. (16-0)

CUSIP: 607525102